Skip to main content

Table 2 Admission characteristics associated with hospital mortality censored at day 60 amongst patients admitted in the pre- and post-implementation periods

From: Impact of a multidisciplinary care bundle for necrotizing skin and soft tissue infections: a retrospective cohort study

  Available data Survivors
n = 151
Non-survivors
n = 38
Unadjusted hazard ratio [95% CI]a p b Adjusted hazard ratio [95% CI]c p d
Inclusion period, n (%)   
 Post-implementation 129 109 (72.2) 20 (52.6) 0.49 [0.26–0.92] 0.026 0.90 [0.43–1.88] 0.780
 Pre-implementation 60 42 (27.8) 18 (47.4)   
Demographical data   
 Age, years, median (IQR) 189 61 [51–72] 71 [59–80] 1.00 [1.00–1.10] 0.018 1.04 [1.01–1.07] 0.011
 Male gender, n (%) 86 (57.0) 24 (63.2) 0.510   
Comorbidities, n (%)   
 Diabetes mellitus 189 58 (38.4) 13 (34.2) 0.520   
 Immunodeficiency 26 (17.2) 18 (47.4) 3.30 [1.70–6.20] < 0.001 2.20 [1.09–4.44] 0.028
  HIV infection 1 (0.7) 0 (0.0) > 0.99   
  Cancer 9 (6.0) 5 (13.2) 0.140   
  Corticosteroids 16 (10.6) 11 (28.9) 2.70 [1.40–5.50] 0.005   
 Obliterating arteritis of the lower limbs 15 (9.9) 5 (13.2) 0.580   
 Liver cirrhosis 4 (2.6) 3 (7.9) 0.100   
 Chronic kidney disease 10 (6.6) 10 (26.3) 3.50 [1.70–7.20] < 0.001
 Chronic alcohol consumption 20 (13.2) 2 (5.3) 0.190   
 Obesity 42 (27.8) 5 (13.2) 0.061   
Prior to admission   
 Time from first symptom, days, median (IQR) 180 5 [3–9] 3 [1–8] 0.410   
 Antibiotic treatment, n (%) 187 99 (65.6) 18 (47.4) 0.51 [0.27–0.97] 0.041 0.36 [0.17–0.75] 0.006
 NSAID use, n (%) 188 38 (25.2) 4 (10.5) 0.076   
 Transferred from another center, n (%) 189 79 (52.3) 21 (55.3) 0.670   
Presentation upon admission   
 Nosocomial infection, n (%) 188 24 (15.9) 13 (34.2) 2.50 [1.30–5.00] 0.007 2.28 [1.00–5.16] 0.049
 Infection site, n (%) 188    
  Inferior limbs 114 (75.5) 29 (76.3) 0.600   
  Superior limbs 15 (9.9) 3 (7.9) 0.690   
  Abdomino-perineal 27 (17.9) 7 (18.4) 0.960   
  Cervico-facial 2 (1.3) 0 (0.0) > 0.99   
  Other 1 (0.7) 0 (0.0) > 0.99   
 Multifocal infection, n (%) 188 14 (9.3) 5 (13.2) 0.540   
 Shock, n (%) 185 48 (31.8) 31 (81.6) 8.20 [3.40–20.00] < 0.001 8.13 [3.26–20.20] < 0.001
  1. HIV human immunodeficiency virus, NSAID non-steroidal anti-inflammatory drugs
  2. Univariable and multivariable analysis by Cox proportional hazards model. Multivariable analysis for 179 patients (10 excluded for missing data on one of the variables)
  3. a,bHazard ratios and p values from the comparison of survivors and non-survivors by univariate cox regression analysis for survival censored at 60 days
  4. c,dAdjusted hazard ratios and p values from a multivariate cox model for survival censored at 60 days. Only patients from the pre- and post-implementation periods were included in the analysis. Variables included in the model were all variables available upon admission associated with mortality in the univariate model with a p value inferior or equal to 0.05. Corticosteroid treatment was included as part of immunodeficiency. Included variables with a p value > 0.1 (chronic kidney disease) in the multivariate model were excluded from the final model